This site provides INTERCEPT product information for International audiences Select your region
The decision to employ pathogen inactivation (PI) technologies should be based on their relative effectiveness at preventing disease transmission, the safety profile of the PI-treated product, the maintenance of in vivo efficacy and the cost-effectiveness of the intervention.
For platelet components, the most important potential benefit is thought to be a reduction in the risk of bacterial contamination and sepsis, a major source of patient morbidity and mortality despite the implementation of multiple interventions.
The INTERCEPT™ Blood System for platelets provides robust, broad-spectrum inactivation, reducing the risks of transfusion-transmitted infections (TTI), including sepsis. In addition, the number of active T-cells is reduced to a level that potentially lowers the risk of transfusion-associated graft versus host disease (TA-GVHD). The safety and efficacy of INTERCEPT platelets has been supported by haemovigilance programmes and several clinical trials.
Over 180,000 INTERCEPT platelet units have been transfused in French and Swiss national haemovigilance (HV) programmes, with no reported transfusion-transmitted infections or sepsis-related fatalities to date.